Vertex Pharmaceuticals Incorporated VRTX NDXSPXR3KPHARMA
Company Overview
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Generates a return on equity of 23.5%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 20.9%.
Revenue has grown at a 10.4% CAGR over the past five years.
Maintains a net profit margin of 35.0%.
Carries low leverage with a debt-to-equity ratio of 0.10.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $12.00B (+8.9% YoY); net profit $3.95B.
- Trailing 12 Months Year-on-year growth — revenue +12.5%, earnings +8.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.4%, profit CAGR 6.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.35% |
| 1 Year: | 12.50% |
Compounded Profit Growth
| 5 Years: | 5.97% |
| 1 Year: | 8.00% |
Stock Price Performance
| 1 Year: | +32.33% |
| 6 Months: | +21.76% |
| 3 Months: | +9.38% |
| 1 Month: | +0.30% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.07 · Neutral
P/E of 30.48 is above the sector median of 25.45 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 23.5%.
- Healthy ROCE of 20.9%.
- Excellent profit margin of 35.0%.
- Compounding revenue at 10.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VRTX Vertex Pharmaceuticals Incorporated NDXSPXR3KPHARMA | 523.93 | 30.48 | $132.71B | 0.00% | 20.91% | 23.54% | 10.35% | 5.97% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 714.72M | 544.13M | 578.16M | 651.63M | 640.80M | 752.16M | 784.53M | 870.11M | 858.43M | 941.29M | 949.83M | 1.41B | 1.52B | 1.52B | 1.54B | 1.63B | 1.72B | 1.79B | 1.98B | 2.10B | 2.20B | 2.33B | 2.37B | 2.49B | 2.48B | 2.69B | 2.65B | 2.77B | - | 2.77B | 2.96B | 3.08B | 3.19B | 2.99B | 3.33B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 363.00M | 407.50M | 414.80M | 466.00M | 392.80M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.41B | 2.56B | 2.66B | 2.72B | 2.59B | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.38B | 1.40B | 1.42B | 1.59B | 1.46B | - |
| Operating Income | -53.70M | -14.33M | 3.35M | -18.73M | 39.64M | 270.84M | 52.71M | -326.04M | 125.74M | 128.90M | 172.88M | 205.65M | 127.72M | 276.81M | 269.96M | 99.33M | 551.47M | 720.22M | 718.03M | 672.24M | 745.79M | 887.80M | -37.90M | 1.05B | 1.04B | 1.11B | 1.13B | 779.00M | 1.03B | 1.04B | 1.14B | -3.51B | 1.12B | - | 1.03B | 1.15B | 1.24B | 1.13B | 1.14B | 1.25B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08B | 1.34B | 1.36B | 1.39B | 1.19B | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.80M | 3.00M | 3.70M | 3.30M | 3.30M | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 730.40M | 1.28B | 1.30B | 1.33B | 1.25B | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 84.10M | 250.10M | 215.90M | 139.90M | 221.50M | - |
| Net Income | -73.73M | -41.63M | -64.53M | -38.84M | 32.95M | 247.76M | 18.00M | -102.95M | 100.68M | 210.26M | 207.36M | 128.75M | 1.55B | 268.63M | 267.43M | 57.52M | 583.23M | 602.75M | 837.27M | 667.43M | 604.19M | 653.10M | 67.00M | 851.90M | 762.10M | 810.50M | 930.50M | 699.80M | 915.70M | 1.04B | 1.10B | -3.59B | 1.05B | - | 646.30M | 1.03B | 1.08B | 1.19B | 1.03B | 1.10B |
| Diluted EPS | - | -0.17 | -0.26 | -0.16 | 0.13 | 0.99 | 0.07 | -0.41 | 0.39 | 0.81 | 0.80 | 0.50 | 5.97 | 1.03 | 1.03 | 0.22 | 2.23 | 2.29 | 3.18 | 2.53 | 2.30 | 2.49 | 0.26 | 3.28 | 2.96 | 3.13 | 3.59 | 2.69 | 3.52 | 3.97 | 4.21 | -13.92 | 4.01 | - | 2.49 | 3.99 | 4.20 | 4.65 | 4.02 | 4.31 |
| R&D Expense | 310.18M | 255.86M | 271.01M | 272.37M | 248.45M | 273.56M | 289.45M | 454.95M | 306.66M | 310.55M | 337.53M | 330.51M | 437.88M | 339.49M | 379.09M | 555.95M | 480.01M | 448.53M | 420.93M | 493.50M | 466.58M | 456.00M | 1.41B | 493.75M | 603.10M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 175.50M | 101.89M | 143.37M | 1.41B | 1.53B | 1.21B | 580.41M | 1.03B | 1.70B | 2.49B | 3.05B | 4.16B | 6.21B | - | 8.93B | 9.87B | 11.02B | 12.00B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08B | 1.26B | 1.53B | 1.65B |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.85B | 8.61B | 9.49B | 10.35B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.60B | 4.83B | 9.72B | 5.80B |
| Operating Income | -462.71M | -614.01M | -696.08M | 113.82M | 46.73M | -610.01M | -692.41M | -466.88M | 9.94M | 123.24M | 635.15M | 1.20B | 2.86B | - | 4.25B | 3.78B | -233.40M | 4.55B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.44B | 4.61B | 486.30M | 4.87B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.80M | 44.10M | 30.60M | 13.30M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.23B | 4.38B | 248.50M | 4.64B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 910.40M | 760.20M | 784.10M | 690.00M |
| Net Income | - | -642.18M | -754.63M | 29.57M | -107.03M | -445.03M | -738.55M | -556.33M | -112.05M | 263.48M | 2.10B | 1.18B | 2.71B | - | 3.32B | 3.62B | -535.60M | 3.95B |
| Diluted EPS | -3.27 | -3.71 | -3.77 | 0.14 | -0.50 | -1.98 | -3.14 | -2.31 | -0.46 | 1.04 | 8.09 | 4.51 | 10.29 | - | 12.82 | 13.89 | -2.08 | 15.32 |
| R&D Expense | 516.91M | 550.27M | 637.42M | 707.71M | 765.90M | 882.10M | 855.51M | 995.92M | 1.05B | 1.32B | 1.42B | 1.75B | 1.83B | 3.05B | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Jan 2018 | Dec 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.96B | 1.73B | 2.20B | 2.76B | 2.32B | 2.33B | 2.50B | 2.90B | 3.55B | 3.56B | 6.25B | 6.26B | 8.32B | 11.75B | 13.43B | 18.15B | 22.73B | 22.53B | 25.64B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.23B | 14.14B | 9.60B | 11.20B |
| Cash & Equivalents | 355.66M | 389.12M | 446.66M | 243.20M | 475.32M | 489.41M | 569.30M | 625.26M | 714.77M | 1.18B | 1.67B | - | 2.65B | - | 3.11B | 5.99B | 6.79B | 10.50B | 10.37B | 4.57B | 5.08B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 460.60M | 738.80M | 1.21B | 1.69B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.44B | 1.56B | 1.61B | 2.05B |
| Total Liabilities | - | - | 859.14M | 1.22B | 1.24B | 1.52B | 962.64M | 1.24B | 1.40B | 1.56B | 1.50B | - | 1.81B | - | 2.23B | 3.06B | 3.33B | 4.24B | 5.15B | 6.12B | 6.98B |
| Current Liabilities | - | - | 284.88M | 474.78M | 392.35M | 432.62M | 397.83M | 368.25M | 506.17M | 792.54M | 807.26M | - | 1.12B | - | 1.33B | 1.88B | 2.14B | 2.74B | 3.55B | 3.56B | 3.86B |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 899.70M | 808.40M | 1.74B | 2.03B |
| Total Equity | 271.30M | 238.87M | 1.10B | 503.97M | 786.84M | 999.18M | 1.36B | 1.08B | 939.97M | 1.16B | 2.03B | - | 4.44B | - | 6.09B | 8.69B | 10.10B | 13.91B | 17.58B | 16.41B | 18.67B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 257.01M | 257.70M | 256.94M | 253.99M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -226.48M | -427.59M | -635.44M | 143.74M | 267.84M | -60.67M | -573.11M | -365.43M | 236.10M | 844.94M | 1.27B | 1.57B | 3.25B | - | 4.13B | 3.54B | -492.60M | 3.63B |
| Investing Cash Flow | -360.65M | -508.73M | 7.30M | - | - | - | - | 268.86M | 51.24M | -483.33M | -202.16M | -1.24B | 99.40M | - | -321.10M | -3.14B | -3.77B | -945.40M |
| Financing Cash Flow | 620.74M | 999.01M | 425.06M | - | - | - | - | 188.92M | 133.27M | 68.40M | -71.22M | 126.80M | -505.30M | - | -67.70M | -562.20M | -1.49B | -2.26B |
| Capital Expenditure | -32.18M | -23.50M | -38.05M | -34.59M | -71.14M | -51.39M | -51.20M | -45.30M | -56.56M | -99.42M | -95.45M | -75.40M | -259.80M | - | -204.70M | -258.40M | -485.40M | -437.60M |
| Free Cash Flow | -258.66M | -451.08M | -673.50M | 109.14M | 196.70M | -112.06M | -624.31M | -410.73M | 179.54M | 745.52M | 1.17B | 1.49B | 2.99B | - | 3.93B | 3.28B | -978.00M | 3.19B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.74B | -166.60M | -5.76B | 424.70M |
| Share Buybacks | - | - | - | - | - | - | - | - | 0 | 0 | 350.04M | 186.00M | 539.10M | 1.43B | 0 | 427.60M | 1.18B | 2.02B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 87.9% | 87.2% | 86.1% | 86.2% |
| Operating Margin % | -263.6% | -602.6% | -485.5% | 8.1% | 3.1% | -50.3% | -119.3% | -45.2% | 0.6% | 5.0% | 20.8% | 28.8% | 46.0% | - | 47.6% | 38.3% | -2.1% | 37.9% |
| Net Margin % | - | -630.3% | -526.3% | 2.1% | -7.0% | -36.7% | -127.2% | -53.9% | -6.6% | 10.6% | 68.8% | 28.3% | 43.7% | - | 37.2% | 36.7% | -4.9% | 32.9% |
| ROE % | - | -58.6% | -149.7% | 3.8% | -10.7% | -32.8% | -68.7% | -59.2% | -9.7% | 13.0% | 47.3% | 19.3% | 31.2% | - | 23.9% | 20.6% | -3.3% | 21.2% |
| ROCE % | - | -36.8% | -55.7% | 6.3% | 2.0% | -31.8% | -35.2% | -23.4% | 0.5% | 4.5% | 12.4% | 17.1% | 28.9% | - | 27.6% | 19.7% | -1.2% | 20.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Capital World Investors | 10.29% | 26.12M | $13.32B |
| 2 | Blackrock Inc. | 9.50% | 24.11M | $12.30B |
| 3 | Capital Research Global Investors | 7.68% | 19.49M | $9.94B |
| 4 | Vanguard Capital Management LLC | 6.53% | 16.58M | $8.46B |
| 5 | State Street Corporation | 4.68% | 11.87M | $6.06B |
| 6 | Invesco Ltd. | 3.17% | 8.04M | $4.10B |
| 7 | JPMORGAN CHASE & CO | 2.57% | 6.52M | $3.32B |
| 8 | Geode Capital Management, LLC | 2.37% | 6.02M | $3.07B |
| 9 | Vanguard Portfolio Management LLC | 1.92% | 4.88M | $2.49B |
| 10 | Capital International Investors | 1.85% | 4.70M | $2.39B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VRTX
Vertex Stock Looks Expensive. Does It Get Cheaper Ahead? - Trefis
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQTzZyVlJOSmprOEk4bHVFbFdpSlZtRWRqY2lnUXVWalFuMjhHT0Q3Z1lSeDhGbVVVdUVoNkJub25rRHk5LTAzUjl3V1cwQkRqblk1dWNXQTFNcGVqSjltZS1MM1F1YXFMWGpPZzRkRmdyQUl1VjVOYjBuUDdYcXNHYTVmdTMxZnBiQzVzRj…
SNDK,VRTX | Stock Prices | Quote Comparison - Yahoo Finance - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE82OWJUTklvNldWLWlxbkFjUjcxSmRhZ0pfRjI1b2NuSndjQ0Ixc0V0M3FaM1ZORkJkT3lhWkI4c0k4Y0hiN0dTcmE1RkRvemdsR0NxcUI2cDBqZw?oc=5" target="_blank">SNDK,VRTX | Stock Prices | Quote Comparison -…
In a 25-person survey, 96% preferred a self-injector to a syringe. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPODFldWwzYzNWZDZHbENTc3l1WkpBSmlzWXNzZFVhVm9yYndpMXBTOVJmcElDNXlmY1FIU1BlRUhhYjV5Qzk3V0ZtNlZXYzBTWktBSDl3MVNoX25iVEFnV3BfV08yNE1GSzZXQlRvcWRnaWxtUjF0WGs4SGd0VGJaQzA4WXA2bFNxMHZlVU…
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know - TradingKey
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQUVBvRU5Ka3lybzlFREp2T2ZtSGJfOXBydTNKU3BQYTNjaTAyTjZudWk1NEwzOFcwY0l3ejlPbjBYUExiM0c2bWROUG1WaHpoNnBiUUwxVU9zcGZXZE5Cc3BKQml1RUVmS1U4d011czNPWjR5SW9RVHhtWDRkWkg0VmdWcmgzbUtPdl93?o…
Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQc0VzMGtueUtMc3NJN09ZTVpOUTJSaHY1WmdrV3VCTzQ1V0lnVVhFX2ZId2VSV1ZtcTN2aG4zN1pRVVVuSGx6STFzRExxY1lQaGxSN0F0Sm42QTNvMERLRFhZN2ZjdmJrdWlETFpZYThPbVpvYldjYTFZMDdwNDFpS0VsX0lqblM4RUFsYg…
Vertex (VRTX) Stock Could Be 32% Undervalued Despite New ALYFTREK Data - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPRVBqa2FOdFJKbHM2Q0JBSzRqckRRbW0zTm85SHdMRGJpNk9wdEQ1YVhFUDhpSW94bmhpVGM2a1dUOVlYRE96OWlwWW1hU3ZzeG5jc0pVZzVHekhwQ2UzbEpHaUdobGk5ZkIweDVjOTVZRDZ5d1lKV2Y5RUFyQlBZQjVtcEZSdWUtNnk3bW…
VRTX — Frequently Asked Questions
What is the current share price of Vertex Pharmaceuticals Incorporated (VRTX)?
As of 2026-10-23 16:27 PDT, Vertex Pharmaceuticals Incorporated (VRTX) trades at $523.93 on NasdaqGS. Its 52-week range is $376.62 to $557.96.
What is the market capitalisation of VRTX?
Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalisation of $132.71B on NasdaqGS.
What is the P/E ratio of VRTX?
VRTX trades at a trailing price-to-earnings (P/E) ratio of 30.48. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 6.36.
What is the return on equity (ROE) of VRTX?
VRTX has a return on equity (ROE) of 23.54%. Its return on capital employed (ROCE) is 20.91%.
Is VRTX a good stock to buy?
This page provides a data-driven analysis of Vertex Pharmaceuticals Incorporated (VRTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.